X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4657) 4657
Book Review (535) 535
Publication (354) 354
Newsletter (11) 11
Conference Proceeding (10) 10
Book Chapter (5) 5
Magazine Article (3) 3
Transcript (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4313) 4313
humans (4261) 4261
dacarbazine - administration & dosage (2878) 2878
female (2683) 2683
male (2639) 2639
oncology (2278) 2278
middle aged (2165) 2165
adult (2106) 2106
dacarbazine - analogs & derivatives (2089) 2089
antineoplastic combined chemotherapy protocols - therapeutic use (2013) 2013
aged (1687) 1687
chemotherapy (1450) 1450
temozolomide (1383) 1383
dacarbazine - therapeutic use (1182) 1182
treatment outcome (1089) 1089
cancer (1018) 1018
doxorubicin - administration & dosage (1008) 1008
melanoma - drug therapy (938) 938
brain neoplasms - drug therapy (875) 875
combined modality therapy (842) 842
dacarbazine - adverse effects (817) 817
dacarbazine (808) 808
vincristine - administration & dosage (784) 784
bleomycin - administration & dosage (750) 750
adolescent (713) 713
radiotherapy (687) 687
antineoplastic combined chemotherapy protocols - adverse effects (680) 680
antineoplastic combined chemotherapy protocols - administration & dosage (660) 660
animals (657) 657
hodgkin disease - drug therapy (656) 656
glioblastoma (650) 650
antineoplastic agents, alkylating - therapeutic use (638) 638
melanoma (631) 631
vinblastine - administration & dosage (627) 627
glioblastoma - drug therapy (583) 583
disease-free survival (568) 568
prognosis (525) 525
antineoplastic agents, alkylating - administration & dosage (524) 524
cell line, tumor (504) 504
dacarbazine - pharmacology (482) 482
drug administration schedule (478) 478
care and treatment (471) 471
survival (465) 465
neoplasm staging (446) 446
procarbazine - administration & dosage (445) 445
cyclophosphamide - administration & dosage (443) 443
mice (431) 431
skin neoplasms - drug therapy (429) 429
retrospective studies (425) 425
prednisone - administration & dosage (424) 424
survival analysis (423) 423
therapy (418) 418
medicine & public health (415) 415
clinical neurology (413) 413
brain neoplasms - pathology (403) 403
melanoma - pathology (397) 397
abridged index medicus (396) 396
survival rate (395) 395
glioma - drug therapy (394) 394
tumors (390) 390
aged, 80 and over (382) 382
gliomas (379) 379
glioblastoma multiforme (377) 377
cisplatin - administration & dosage (360) 360
trial (359) 359
antineoplastic agents - therapeutic use (357) 357
follow-up studies (357) 357
antineoplastic agents - administration & dosage (349) 349
malignant glioma (346) 346
young adult (343) 343
metastatic melanoma (338) 338
melanoma - secondary (336) 336
hodgkin disease - pathology (303) 303
child (301) 301
pharmacology & pharmacy (299) 299
research (299) 299
hematology (298) 298
antineoplastic agents, alkylating - adverse effects (296) 296
brain neoplasms - therapy (296) 296
drug therapy (295) 295
glioblastoma - pathology (295) 295
mechlorethamine - administration & dosage (287) 287
phase-ii (287) 287
vinblastine (287) 287
brain neoplasms - mortality (284) 284
apoptosis (278) 278
skin neoplasms - pathology (277) 277
analysis (276) 276
remission induction (275) 275
surgery (275) 275
antineoplastic agents (273) 273
neoplasm metastasis (273) 273
hodgkin disease - radiotherapy (272) 272
malignant-melanoma (270) 270
glioma (267) 267
brain neoplasms - radiotherapy (263) 263
dose-response relationship, drug (261) 261
time factors (256) 256
chemotherapy, adjuvant (253) 253
antimitotic agents (252) 252
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4296) 4296
Japanese (101) 101
German (68) 68
French (67) 67
Spanish (37) 37
Russian (34) 34
Polish (28) 28
Chinese (17) 17
Hungarian (9) 9
Italian (6) 6
Bulgarian (5) 5
Hebrew (4) 4
Czech (2) 2
Dutch (2) 2
Portuguese (2) 2
Finnish (1) 1
Korean (1) 1
Norwegian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1188 - 1194
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2017, Volume 35, Issue 16, pp. 1786 - 1794
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2010, Volume 28, Issue 27, pp. 4199 - 4206
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 3, pp. 163 - 168
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 9, pp. 907 - 913
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
INHIBIN-B | PRESERVATION | OUTCOME MEASURE | OVARIAN RESERVE | ONCOLOGY | TERM FOLLOW-UP | DISEASE | FEMALE CANCER SURVIVORS | ANTI-MULLERIAN HORMONE | CHEMOTHERAPY | SERUM MARKER | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2010, Volume 151, Issue 2, pp. 159 - 166
Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B-cell... 
cyclophosphamide | clinical trials | vincristine | doxorubicin | prednisone (CHOP) | T-cell lymphoma | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | IFOSFAMIDE | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | THERAPY | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Ifosfamide - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Adolescent | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Anthracyclines | Cyclophosphamide | Corticosteroids | Etoposide | Clinical trials | Product development | Prednisone | Non-Hodgkin's lymphomas | T cells | double prime B-cell lymphoma | Cell survival | Vinblastine | Ifosfamide | Toxicity | Doxorubicin | Survival | Vincristine | Cisplatin | Dacarbazine | Bleomycin | Remission | double prime T-cell lymphoma | Anaplastic large-cell lymphoma | expressed sequence tags | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 36, pp. 9198 - 9207
Journal Article